Essential Therapeutics (ETRX) formerly Microcide (MCDE Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Essential Therapeutics (ETRX) formerly Microcide (MCDE

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (234)	1/15/2000 3:19:00 AM
From: WTDEC	Read Replies (1) of 415

Rick, Yes. Even at today's capital value of $116 million, I think MCDE is very cheap, but I worry about price pull back as the new investors look for instant gratification and fail to get same. Longer term, I believe MCDE has 10X+ type potential. Rurka was strongly optimistic about their prospects going forward. I don't know him all that well but have had the impression he is quite conservative, so his excitement struck me as particularly meaningful. You know him better, so please let me know if my read is off. Rurka described in considerable detail their Targeted Genomics program, which utilizes bacterial, fungal and viral genetics to discover new classes of antimicrobials and other novel treatments for infectious diseases. I was surprised that they have already identified 102 targets through this program. The Phase I clinical trial of the antibiotic RWJ-54428, the novel cephalosporin type drug partnered with J&J, is well underway. Best regards, Walter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next